Loading...

APC anti-mouse CD274 (B7-H1, PD-L1) Antibody

Pricing & Availability
Clone
10F.9G2 (See other available formats)
Regulatory Status
RUO
Other Names
B7-H1, PD-L1
Isotype
Rat IgG2b, κ
Ave. Rating
Submit a Review
Product Citations
publications
10Fdot9G2_APC_040610
C57/B6 mouse splenocytes were stained with anti-CD274 (clone 10F.9G2) APC (pink line) or rat IgG2b, κ APC (purple line).
  • 10Fdot9G2_APC_040610
    C57/B6 mouse splenocytes were stained with anti-CD274 (clone 10F.9G2) APC (pink line) or rat IgG2b, κ APC (purple line).
Compare all formats See APC spectral data
Cat # Size Price Quantity Check Availability Save
124311 25 µg 71€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
124312 100 µg 216€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD274, also known as B7-H1 or programmed death ligand 1 (PD-L1), is a 40 kD type I transmembrane protein and a member of the B7 family within the immunoglobulin receptor superfamily. It is expressed on T cells, B cells, NK cells, dendritic cells, IFN-γ activated endothelial cells, and monocytes. B7-H1 is one of the ligands of PD-1. The interaction of B7-H1 with PD-1 plays an important role in the inhibition of T cell responses. Other studies have shown that B7-H1 is able to costimulate T cell growth and cytokine production. CD274 is involved in costimulation essential for T cell proliferation and production of IL-10 and IFN-γ, in an IL-2-dependent and a PD-1-independent manner. Its interaction with PD-1 inhibits T cell proliferation and cytokine production.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography and conjugated with APC under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.25 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Red Laser (633 nm)
Application Notes

Additional reported applications (for the relevant formats) include: immunofluorescence4, blocking6,7,8,9, and immunohistochemistry of acetone-fixed frozen sections4, 11. The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 124303). For highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 124318) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin <0.01 EU/µg).

Application References
  1. Maier H, et al. 2007. J. Immunol. 178:2714.
  2. Meng Q, et al. 2006. Invest. Ophthalmol. Vis. Sci. 47:4444. PubMed
  3. Scarlett UK, et al. 2012. J Exp Med. 209:495. PubMed
  4. Grabie N, et al. 2007. Circulation 116:2062. (IF, IHC)
  5. Paterson AM, et al. 2011. J. Immunol. 187:1097.
  6. Channappanavar R, et al. 2012. PLoS One 7:e39757. (Block)
  7. Schreiber HA, et al. 2010. PLoS One 5:e11453. (Block) PubMed
  8. Muthumani K, et al. 2011. J. Immunol. 187:2932. (Block) PubMed
  9. Cripps JG, et al. 2010. Hepatology 52:1350. (Block) PubMed
  10. Murakami R, et al. 2013. PLoS One. 8:73270. PubMed
  11. Riella LV, et al. 2011. Am. J. Transplant 11:832-40. (IHC)
  12. Lei GS, et al. 2015. Infect Immun. 83:572. PubMed
Product Citations
  1. Saha D et al. 2017. Cancer cell. 32(2):253-267 . PubMed
  2. Chan LC, et al. 2019. J Clin Invest. 129:3324. PubMed
  3. Chen H, et al. 2023. Nat Commun. 14:941. PubMed
  4. Gu J, et al. 2023. J Cell Biochem. 124:557. PubMed
  5. Zhang X, et al. 2023. Heliyon. 9:e13490. PubMed
  6. Tsai KC, et al. 2023. Mar Drugs. 21:. PubMed
  7. Gu T, et al. 2023. Front Immunol. 14:1145028. PubMed
  8. Changsheng H, et al. 2023. Sci Adv. 9:eade4186. PubMed
  9. Song S, et al. 2023. Bioact Mater. 28:358. PubMed
  10. Schnell A, et al. 2021. Cell. 184:6281. PubMed
  11. Yang Z, et al. 2022. Cancer Discov. 12:1942. PubMed
  12. Wang X, et al. 2022. Sci Adv. 8:eabn0071. PubMed
  13. Yang H, et al. 2023. Cell Death Differ. 30:560. PubMed
  14. An HW, et al. 2022. Cell Rep. 41:111878. PubMed
  15. Kemna J, et al. 2023. Nat Immunol. 24:414. PubMed
  16. Reticker-Flynn NE, et al. 2022. Cell. 185:1924. PubMed
  17. Ngiow S, et al. 2016. Cancer Res . 76: 6266 - 6277. PubMed
  18. Yonemitsu K, et al. 2022. Sci Rep. 12:12007. PubMed
  19. Tatsuguchi T, et al. 2022. Int Immunol. 34:277. PubMed
  20. Khan KA, et al. 2020. NPJ Breast Cancer. 6:29. PubMed
  21. Pierini S, et al. 2021. J Immunother Cancer. 9:. PubMed
  22. Kim TJ, et al. 2019. Nat Commun. 10:3258. PubMed
  23. Lin R, et al. 2020. Sci Rep. 10:14397. PubMed
  24. Park S, et al. 2021. Front Immunol. 11:620166. PubMed
  25. Kiritsy MC, et al. 2021. Elife. 10:. PubMed
  26. Aguilera T, et al. 2016. Nat Commun. 7:13898. PubMed
  27. Zhang Y, et al. 2020. Oncol Lett. 1.053472222. PubMed
  28. Fu Y, et al. 2020. Sci Rep. 10:9027. PubMed
  29. Choi H et al. 2019. Cell Rep. 27(3):806-819 . PubMed
  30. Zhang C, et al. 2022. J Extracell Vesicles. 11:e12209. PubMed
  31. Ren J, et al. 2021. Theranostics. 11:304. PubMed
  32. Chen L, et al. 2020. Cancer Immunol Res. 0.457638889. PubMed
  33. Findlay EG, et al. 2019. Oncoimmunology. 8:1608106. PubMed
  34. Bommireddy R, et al. 2020. Vaccines (Basel). 8:. PubMed
  35. Zhang C, et al. 2020. Cell Metabolism. 31(1):148-161.e5.. PubMed
  36. Cousin N, et al. 2021. Cancer Res. 81:4133. PubMed
  37. Davidson S, et al. 2020. Cell Reports. 31(7):107628. PubMed
  38. Pein M, et al. 2020. Nat Commun. 11:1494. PubMed
  39. Khan KA, et al. 2020. NPJ Breast Cancer. 6:29. PubMed
  40. Zhou KX, et al. 2021. J Immunol Res. 2021:6694392. PubMed
  41. Tu J, et al. 2022. Theranostics. 12:747. PubMed
  42. Zhou L, et al. 2020. Clin Cancer Res. 26:290. PubMed
  43. Zhang P, et al. 2022. BMC Med. 20:435. PubMed
  44. Guo L, et al. 2021. Front Immunol. 12:785457. PubMed
  45. Lovisa S, et al. 2020. Sci Signal. 13:00. PubMed
  46. Hu Q, et al. 2018. Nat Biomed Eng. 0.660416667. PubMed
  47. Poon E, et al. 2017. J Immunother Cancer. 10.1186/s40425-017-0268-8. PubMed
  48. Kennedy EM, et al. 2022. Nat Commun. 13:5907. PubMed
  49. Pradhan K, et al. 2021. Front Immunol. 12:778830. PubMed
  50. Holokai L, et al. 2020. Cancers (Basel). 12:00. PubMed
  51. Ying Zhang et al. 2017. Cancer cell. 32(3):377-391 . PubMed
  52. Rashid MH, et al. 2021. Oncol Rep. 45:1171. PubMed
  53. Huang L, et al. 2021. Breast Cancer Res Treat. Online ahead of print. PubMed
  54. Koikawa K, et al. 2021. Cell. 184:4753. PubMed
  55. Vardhana SA, et al. 2020. Nat Immunol. 1.584722222. PubMed
  56. Fukumoto T, et al. 2019. Cancer Res. 79:5482. PubMed
  57. Zhang X, et al. 2021. Mol Cancer Res. 19:1076. PubMed
  58. Almishri W, et al. 2015. J Hepatol. 63: 943-951. PubMed
  59. Williams JB, et al. 2020. Nat Commun. 0.876388889. PubMed
  60. Yuan M, et al. 2022. Oxid Med Cell Longev. 2022:5479491. PubMed
  61. Shen ZY, et al. 2021. Front Immunol. 12:589200. PubMed
  62. Barbet G, et al. 2018. Immunity. 48:584. PubMed
  63. Iwata TN, et al. 2018. Mol Cancer Ther. 17:1494. PubMed
  64. Franklin DA, et al. 2020. JCI Insight. 5:. PubMed
  65. Baldwin LA, et al. 2022. Nat Commun. 13:6539. PubMed
  66. Yi M, et al. 2022. J Hematol Oncol. 15:142. PubMed
  67. Li Q, et al. 2022. Front Oncol. 12:841977. PubMed
  68. Lindhorst A, et al. 2021. Cell Death Dis. 12:579. PubMed
  69. Vogel A, et al. 2022. Cell Rep. 38:110420. PubMed
  70. Kataru RP, et al. 2019. Cancer Immunol Res. 7:1345. PubMed
  71. Renner K, et al. 2020. Cell Reports. 29(1):135-150.e9.. PubMed
  72. Wang R, et al. 2022. J Immunother Cancer. 10:. PubMed
  73. Wang C, et al. 2018. Sci Transl Med. 10. PubMed
  74. Zheng C, et al. 2022. Acta Pharm Sin B. 12:3726. PubMed
  75. Shen H, et al. 2022. Nat Commun. 13:5013. PubMed
  76. Lin J, et al. 2021. Cancer Immunol Res. 9:1413. PubMed
  77. Liu YS, et al. 2021. Cancers (Basel). 13:. PubMed
  78. Luna-Yolba R, et al. 2021. Cancers (Basel). 13: . PubMed
  79. Freed-Pastor WA, et al. 2021. Cancer Cell. 39:1342. PubMed
  80. Shaashua L, et al. 2022. Nat Commun. 13:6513. PubMed
  81. RL M, et al. 2015. Proc Natl Acad Sci U S A. 112:6506-6514. PubMed
  82. Lerbs T, et al. 2020. JCI Insight. 5:00. PubMed
  83. Luo N, et al. 2018. Nat Commun. 0.547222222. PubMed
  84. Li CY, et al. 2022. Int J Mol Sci. 23:. PubMed
  85. Song X, et al. 2022. Transl Oncol. 15:101306. PubMed
RRID
AB_10612935 (BioLegend Cat. No. 124311)
AB_10612935 (BioLegend Cat. No. 124312)

Antigen Details

Structure
40 kD type I transmembrane protein member of B7 family within the immunoglobulin receptor superfamily
Distribution

T cells, B cells, NK cells, dendritic cells, IFN-γ activated endothelial cells, and monocytes

Ligand/Receptor
PD-1 (PDCD1)
Cell Type
B cells, Dendritic cells, Endothelial cells, Monocytes, NK cells, T cells
Biology Area
Cancer Biomarkers, Costimulatory Molecules, Immunology
Molecular Family
Adhesion Molecules, CD Molecules, Immune Checkpoint Receptors
Antigen References

1. Sharpe A, et al. 2007. Nat. Immunol. 8:239.
2. Dong H, et al. 1999. Nat. Med. 5:1365.
3. Freeman G, et al. 2000. J. Exp. Med. 192:1027.

Gene ID
60533 View all products for this Gene ID
UniProt
View information about CD274 on UniProt.org
Go To Top Version: 2    Revision Date: 12.22.2014

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account